Skip to main content
. 2020 Nov 10;50:101115. doi: 10.1016/j.molmet.2020.101115

Figure 4.

Figure 4

Proteins are shown that either promote or inhibit the development and progression of steatosis to NASH and systemic comorbidities (e.g., insulin resistance, CVD, etc.) or only facilitate the development of advanced liver diseases including NASH. ∗Carriers of the TM6SF2 E167K variant have an increased risk of NAFLD/NASH, insulin resistance, and type 2 diabetes, but are protected from CVD.